JP2018522822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522822A5 JP2018522822A5 JP2017560196A JP2017560196A JP2018522822A5 JP 2018522822 A5 JP2018522822 A5 JP 2018522822A5 JP 2017560196 A JP2017560196 A JP 2017560196A JP 2017560196 A JP2017560196 A JP 2017560196A JP 2018522822 A5 JP2018522822 A5 JP 2018522822A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tumor
- mutation
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 230000035772 mutation Effects 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 108060006698 EGF receptor Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 231100000221 frame shift mutation induction Toxicity 0.000 claims 3
- 230000037433 frameshift Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 102100039788 GTPase NRas Human genes 0.000 claims 2
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 2
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 2
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims 2
- 102000016914 ras Proteins Human genes 0.000 claims 2
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 2
- 229950010550 resiquimod Drugs 0.000 claims 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 2
- 208000002918 testicular germ cell tumor Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- -1 trastuzumab Chemical compound 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 241000272478 Aquila Species 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229920002498 Beta-glucan Polymers 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000011786 HLA-A Antigens Human genes 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 claims 1
- 239000012648 POLY-ICLC Substances 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 108010017271 denileukin diftitox Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940056913 eftilagimod alfa Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 229940100027 ontak Drugs 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 108700002563 poly ICLC Proteins 0.000 claims 1
- 229940115270 poly iclc Drugs 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 102200124923 rs121913254 Human genes 0.000 claims 1
- 102200006531 rs121913529 Human genes 0.000 claims 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021114423A JP7282834B2 (ja) | 2015-05-20 | 2021-07-09 | 共通ネオ抗原 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562179877P | 2015-05-20 | 2015-05-20 | |
| US62/179,877 | 2015-05-20 | ||
| US201662389377P | 2016-02-23 | 2016-02-23 | |
| US62/389,377 | 2016-02-23 | ||
| PCT/US2016/033452 WO2016187508A2 (en) | 2015-05-20 | 2016-05-20 | Shared neoantigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114423A Division JP7282834B2 (ja) | 2015-05-20 | 2021-07-09 | 共通ネオ抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522822A JP2018522822A (ja) | 2018-08-16 |
| JP2018522822A5 true JP2018522822A5 (enExample) | 2019-06-20 |
| JP6913032B2 JP6913032B2 (ja) | 2021-08-04 |
Family
ID=56203902
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560196A Active JP6913032B2 (ja) | 2015-05-20 | 2016-05-20 | 共通ネオ抗原 |
| JP2021114423A Active JP7282834B2 (ja) | 2015-05-20 | 2021-07-09 | 共通ネオ抗原 |
| JP2023081513A Pending JP2023103405A (ja) | 2015-05-20 | 2023-05-17 | 共通ネオ抗原 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114423A Active JP7282834B2 (ja) | 2015-05-20 | 2021-07-09 | 共通ネオ抗原 |
| JP2023081513A Pending JP2023103405A (ja) | 2015-05-20 | 2023-05-17 | 共通ネオ抗原 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10835585B2 (enExample) |
| EP (1) | EP3297660A2 (enExample) |
| JP (3) | JP6913032B2 (enExample) |
| KR (2) | KR20180010229A (enExample) |
| CN (2) | CN116196401A (enExample) |
| AU (3) | AU2016264623B2 (enExample) |
| BR (1) | BR112017024797A2 (enExample) |
| CA (1) | CA2986235A1 (enExample) |
| CL (2) | CL2017002945A1 (enExample) |
| CO (1) | CO2017012835A2 (enExample) |
| CR (3) | CR20170584A (enExample) |
| EC (1) | ECSP17084137A (enExample) |
| HK (1) | HK1252267A1 (enExample) |
| IL (3) | IL302102A (enExample) |
| MX (3) | MX2017014700A (enExample) |
| MY (1) | MY190974A (enExample) |
| PE (1) | PE20180670A1 (enExample) |
| PH (1) | PH12017502321A1 (enExample) |
| RU (1) | RU2733754C2 (enExample) |
| TW (3) | TW202523682A (enExample) |
| WO (1) | WO2016187508A2 (enExample) |
Families Citing this family (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| ME03010B (me) | 2008-10-22 | 2018-10-20 | Array Biopharma Inc | Jedinjenja supstituisanog pirazol0[1,5-]pirimidina као inhibitori trk kinaze |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PL2918588T3 (pl) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| TWI767858B (zh) | 2014-11-16 | 2022-06-11 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| WO2016187508A2 (en) * | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
| CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| TWI765875B (zh) | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | 新抗原辨識、製造及用途 |
| WO2017124147A1 (en) * | 2016-01-19 | 2017-07-27 | The University Of Western Australia | Novel biomolecule conjugates and uses therefor |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| EP3475434A4 (en) | 2016-03-24 | 2020-07-29 | Nantcell, Inc. | SEQUENCES AND SEQUENCES ARRANGEMENTS FOR PRESENTATION OF NEO-EPITOPIA |
| PT3436048T (pt) * | 2016-03-31 | 2025-08-06 | Biontech Us Inc | Neoantigénios e métodos da sua utilização |
| DK3439662T3 (da) | 2016-04-04 | 2024-09-02 | Loxo Oncology Inc | Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| WO2017177207A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene, Llc | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| WO2017190218A1 (en) * | 2016-05-06 | 2017-11-09 | University Health Network | Liquid-biopsy signatures for prostate cancer |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| WO2018098636A1 (zh) * | 2016-11-29 | 2018-06-07 | 深圳华大基因研究院 | 多肽及其应用 |
| JP2020507557A (ja) | 2016-12-01 | 2020-03-12 | ナントミクス，エルエルシー | 腫瘍抗原性の処理および提示 |
| KR102898130B1 (ko) | 2016-12-09 | 2025-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | Crispr 이펙터 시스템 기반 진단 |
| WO2018119351A1 (en) | 2016-12-23 | 2018-06-28 | Bluefin Biomedicine, Inc. | Anti-sez6l2 antibodies and antibody drug conjugates |
| WO2018129624A1 (en) * | 2017-01-13 | 2018-07-19 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| CA3050109A1 (en) | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| MX2019009070A (es) | 2017-02-01 | 2019-10-30 | Modernatx Inc | Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. |
| CN110709094A (zh) | 2017-02-03 | 2020-01-17 | 威斯康星州医药大学股份有限公司 | Kras肽疫苗组合物及其使用方法 |
| CN106868133A (zh) * | 2017-02-24 | 2017-06-20 | 北京致成生物医学科技有限公司 | 一种监测肿瘤发生发展的产品及其应用 |
| US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
| EP3596218B1 (en) | 2017-03-15 | 2023-08-23 | The Broad Institute, Inc. | Crispr effector system based diagnostics for virus detection |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN108659114B (zh) * | 2017-04-01 | 2022-10-21 | 中国科学院广州生物医药与健康研究院 | 识别pasd1抗原短肽的tcr |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| IL270132B2 (en) | 2017-04-24 | 2024-12-01 | Nantcell Inc | Neoepitope vectors and methods for them |
| WO2018208856A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| US20200061112A1 (en) * | 2017-05-10 | 2020-02-27 | University Of Connecticut | Dendritic Cells as a Novel Delivery System for Immunotherapy |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| JP7381345B2 (ja) * | 2017-05-16 | 2023-11-15 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｍａｎａボディおよび使用方法 |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| CN120555350A (zh) * | 2017-06-22 | 2025-08-29 | Neogap 治疗学公司 | T细胞扩增方法及用途 |
| EP4327819A3 (en) * | 2017-06-30 | 2024-05-29 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | Treatment of haematological malignancies |
| NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
| US20220305102A1 (en) * | 2017-06-30 | 2022-09-29 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | Treatment of haematological malignancies |
| CN107325171A (zh) * | 2017-07-06 | 2017-11-07 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑7及其在制备治疗非小细胞肺癌的药物中的应用 |
| CN107188955A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用 |
| EP3648790A1 (en) * | 2017-07-07 | 2020-05-13 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
| KR102709778B1 (ko) * | 2017-07-12 | 2024-09-26 | 노우스콤 아게 | 미세부수체 불안정성(msi) 암의 예방 및 치료를 위한 공유된 종양 신생항원을 기반으로 한 범용 백신 |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| EP3666887A4 (en) * | 2017-08-10 | 2021-09-01 | Good T Cells, Inc. | T-CELL ACTIVATION METHOD FOR CANCER TREATMENT |
| AU2018328220C1 (en) * | 2017-09-05 | 2026-01-08 | Seattle Project Corp. | Neoantigen identification for T-cell therapy |
| JP7320840B2 (ja) * | 2017-09-11 | 2023-08-04 | 国立大学法人北海道大学 | 癌治療薬 |
| FI3688027T3 (fi) * | 2017-09-29 | 2025-12-09 | Us Health | Mutatoidun p53:n tunnistavia t-solureseptoreita |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| CA3079565A1 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| CA3087362A1 (en) | 2018-01-29 | 2019-08-01 | The Broad Institute, Inc. | Crispr effector system based diagnostics |
| EP3754022A4 (en) * | 2018-02-15 | 2021-09-29 | National University Corporation Asahikawa Medical University | CANCER ANTIGENIC PEPTIDE |
| US20210238690A1 (en) * | 2018-04-26 | 2021-08-05 | Intellexon Gmbh | Hla-j and medical/diagnostic uses thereof |
| AU2019263233B2 (en) * | 2018-05-01 | 2024-08-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors which recognize mutated EGFR |
| CN108588201B (zh) * | 2018-05-11 | 2019-08-09 | 浙江省人民医院 | 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置 |
| EP3806961A4 (en) * | 2018-05-11 | 2022-10-19 | Memorial Sloan Kettering Cancer Center | T LYMPHOCYTE RECEPTORS TARGETING PIK3CA MUTATIONS AND THEIR USES |
| CN112941155B (zh) * | 2018-05-14 | 2023-07-14 | 北京艾克伦医疗科技有限公司 | 具有茎环结构的dna引物对及其应用 |
| EP3796927A4 (en) * | 2018-05-23 | 2022-04-20 | Gritstone bio, Inc. | Shared antigens |
| JP2021525549A (ja) * | 2018-05-25 | 2021-09-27 | ザ ウィスター インスティテュート | 腫瘍特異的ネオ抗原およびその使用方法 |
| CN108728529B (zh) * | 2018-06-06 | 2020-08-04 | 青岛泱深生物医药有限公司 | Znf770基因在制备诊治子痫前期的产品中的应用 |
| CN110577953B (zh) * | 2018-06-11 | 2024-02-20 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
| CN109142729B (zh) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | 一种肺癌标志物抗-hmgb3自身抗体及其应用 |
| US11357816B2 (en) * | 2018-06-18 | 2022-06-14 | Centre National De La Recherche Scientifique (Cnrs) | Ligand controling interaction between gags with their effector molecules and use thereof |
| TW202015719A (zh) * | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| WO2019246315A1 (en) * | 2018-06-19 | 2019-12-26 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| GB201810358D0 (en) | 2018-06-25 | 2018-08-08 | Univ College Cardiff Consultants Ltd | Cancer-specific t-cell receptors |
| IL321692A (en) | 2018-07-26 | 2025-08-01 | Curevac Netherlands B V | Cancer vaccines for colorectal cancer |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| CA3106562A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| WO2020022900A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| CA3106570A1 (en) * | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
| US20210252123A1 (en) * | 2018-07-26 | 2021-08-19 | Frame Pharmaceuticals B.V. | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER |
| WO2020023921A1 (en) | 2018-07-27 | 2020-01-30 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US20220160870A1 (en) * | 2018-08-28 | 2022-05-26 | Roche Innovation Center Copenhagen A/S | Neoantigen engineering using splice modulating compounds |
| CN113039612A (zh) * | 2018-08-28 | 2021-06-25 | 赛科维有限两合公司 | 分级和/或选择肿瘤特异性新抗原的方法 |
| KR20210058825A (ko) * | 2018-09-05 | 2021-05-24 | 백심 아게 | 병용 요법용 신생항원 표적화 dna 백신 |
| CN109022585A (zh) * | 2018-09-10 | 2018-12-18 | 路君 | Pbld基因在制备肾透明细胞癌诊断和预测预后药物中的应用 |
| EP3854418A4 (en) * | 2018-09-20 | 2022-07-27 | Daiichi Sankyo Company, Limited | TREATMENT OF HER3 MUTANT CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109207431B (zh) * | 2018-10-12 | 2021-10-15 | 武汉大学 | 一种抑制人癌基因STAT3的α亚型表达的方法 |
| CN109486935A (zh) * | 2018-10-18 | 2019-03-19 | 中国医学科学院北京协和医院 | 作为骨质疏松症诊治靶标的aknad1基因 |
| CN109321569B (zh) * | 2018-10-29 | 2022-04-12 | 迈杰转化医学研究(苏州)有限公司 | 一种引物探针组合物及其应用 |
| CN111116754A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性tcr及其应用 |
| WO2020090979A1 (ja) * | 2018-10-31 | 2020-05-07 | 味の素株式会社 | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| WO2020092705A1 (en) * | 2018-10-31 | 2020-05-07 | University Of Virginia Patent Foundation | Self-assembling peptides and hydrogels |
| EP3873922A4 (en) * | 2018-11-01 | 2022-08-03 | The Broad Institute, Inc. | IDENTIFICATION OF TUMORS RESPONSIVE TO PDE3 MODULATORS |
| CN109504771A (zh) * | 2018-11-19 | 2019-03-22 | 北京大学深圳医院（北京大学深圳临床医学院） | Adcy2作为乳腺癌的分子标记物的应用 |
| CN109438570B (zh) * | 2018-11-28 | 2021-07-20 | 生命谷（海南）生物科技股份有限公司 | 肿瘤相关基因fgfr3突变短肽及其应用 |
| CN109371026A (zh) * | 2018-12-11 | 2019-02-22 | 宁夏医科大学总医院 | 一种环状RNA hsa_circACACB_035及其特异性扩增引物和应用 |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| CN113226473B (zh) | 2018-12-20 | 2025-05-13 | 美国安进公司 | Kif18a抑制剂 |
| GB201821207D0 (en) | 2018-12-24 | 2019-02-06 | Tcer Ab | Immunotherapy therapy |
| CN111363816B (zh) * | 2018-12-26 | 2024-02-02 | 广州康立明生物科技股份有限公司 | 基于pax3和zic4基因的肺癌诊断试剂及试剂盒 |
| CN109576362B (zh) * | 2018-12-28 | 2020-09-04 | 青岛泱深生物医药有限公司 | 阿尔茨海默诊治用标志物fam170a |
| TWI852977B (zh) * | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
| JP7667569B2 (ja) | 2019-01-15 | 2025-04-23 | コーネル ユニバーシティー | 組換えラブリシン、並びにそれを使用するための組成物及び方法 |
| CN109887553B (zh) * | 2019-01-29 | 2021-01-26 | 杭州纽安津生物科技有限公司 | 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法 |
| WO2020168047A1 (en) * | 2019-02-13 | 2020-08-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination of t-cell therapy and targeted therapy for treating therapy-resistant melanoma with mutations in the braf gene |
| US20200291355A1 (en) | 2019-02-20 | 2020-09-17 | Rubius Therapeutics, Inc. | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
| CN109735624A (zh) * | 2019-03-14 | 2019-05-10 | 台州市立医院 | 基因标志物在甲状腺癌诊断中的应用 |
| US12098175B2 (en) | 2019-03-21 | 2024-09-24 | Institute For Research In Biomedicine | Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof |
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| AU2020277496A1 (en) * | 2019-05-23 | 2021-12-02 | Christiana Care Gene Editing Institute, Inc. | Gene knockout of variant NRF2 for treatment of cancer |
| KR20220016137A (ko) | 2019-05-30 | 2022-02-08 | 그릿스톤 바이오, 인코포레이티드 | 변형된 아데노바이러스 |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| US11306122B2 (en) * | 2019-06-14 | 2022-04-19 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor |
| CN114245745A (zh) | 2019-06-20 | 2022-03-25 | 纪念斯隆-凯特琳癌症中心 | 靶向pik3ca突变的t细胞受体及其用途 |
| CN110358827A (zh) * | 2019-07-09 | 2019-10-22 | 中国人民解放军第四军医大学 | Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备 |
| CN110358831B (zh) * | 2019-07-11 | 2021-12-24 | 江苏医药职业学院 | 检测跨膜蛋白41a表达水平的试剂的应用和试剂盒 |
| US12486334B2 (en) | 2019-07-12 | 2025-12-02 | The Regents Of The University Of California | Chemically controlled monoclonal antibody target engagement |
| CA3147606A1 (en) * | 2019-07-16 | 2021-01-21 | Washington University | Anti-grp78 antibodies and method of use thereof |
| JP2022543583A (ja) * | 2019-07-30 | 2022-10-13 | ブレイクバイオ コーポレイション | 固形腫瘍の治療方法 |
| EP4013494A1 (en) | 2019-08-12 | 2022-06-22 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| EP4017964A1 (en) * | 2019-08-19 | 2022-06-29 | Universität Basel | Cell therapy methods |
| CN112402612B (zh) * | 2019-08-21 | 2023-05-26 | 苏州蓝马医疗技术有限公司 | 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法 |
| KR20220070487A (ko) * | 2019-09-26 | 2022-05-31 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 면역원성 egfr 펩타이드 조성물 및 암의 치료에서 그의 용도 |
| US20220396636A1 (en) * | 2019-11-06 | 2022-12-15 | Ohio State Innovation Foundation | Targeting circular pcmtd1 in leukemias with p53 mutations and/or bcr/abl fusions |
| US20230059675A1 (en) * | 2019-11-07 | 2023-02-23 | Shenzhen Gino Biotechnology Co., Ltd. | Tumor-specific polypeptide sequence and use thereof |
| AU2020384374A1 (en) * | 2019-11-15 | 2022-06-09 | Seattle Project Corp. | Antigen-binding proteins targeting shared neoantigens |
| AU2020386834A1 (en) * | 2019-11-22 | 2022-06-02 | National University Of Singapore | Method and system for identifying and validating shared candidate antigens and shared antigen-specific T lymphocyte pairs |
| WO2021133742A1 (en) | 2019-12-23 | 2021-07-01 | The Regents Of The University Of California | Stabilization of mhc complexes |
| CN113117081B (zh) * | 2019-12-30 | 2024-12-24 | 上海海洋大学 | ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法 |
| IL294290A (en) | 2019-12-31 | 2022-08-01 | Elixirgen Therapeutics Inc | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| CN111116728B (zh) * | 2020-01-13 | 2021-04-27 | 郑州大学 | 肿瘤特异性抗原ctl表位肽及其应用 |
| KR20220131233A (ko) * | 2020-01-21 | 2022-09-27 | 상하이 바이오트로이 바이오테크니크 컴퍼니, 리미티드 | Semg2 항체 및 이의 용도 |
| WO2021168355A1 (en) * | 2020-02-20 | 2021-08-26 | Gritstone Bio, Inc. | Antigen-binding proteins targeting kklc-1 shared antigen |
| CN111303268B (zh) * | 2020-03-10 | 2021-08-27 | 江苏兰恩生物治疗技术研究院有限公司 | 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗 |
| CN113388023A (zh) * | 2020-03-18 | 2021-09-14 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| WO2021228999A1 (en) * | 2020-05-12 | 2021-11-18 | Institut Curie | Neoantigenic epitopes associated with sf3b1 mutations |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| CN113817740B (zh) * | 2020-06-19 | 2024-07-09 | 中国科学院化学研究所 | 一种核酸适配体识别并结合ptprf及其相关功能的应用研究 |
| CN111718405B (zh) * | 2020-06-30 | 2022-09-13 | 青岛海兰深生物科技有限公司 | 一种检测抗胰腺癌天然抗体的组合物、试剂盒和方法 |
| US20240279740A1 (en) * | 2020-07-02 | 2024-08-22 | The Johns Hopkins University | Methylated markers for accurate detection of primary central nervous system and systemic diffuse large b cell lymphoma |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| AR123767A1 (es) | 2020-10-13 | 2023-01-11 | Janssen Biotech Inc | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii |
| US12440537B1 (en) * | 2020-10-13 | 2025-10-14 | Washington University | Compositions and methods for treating skin diseases, disorders, or conditions |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| JP2023551204A (ja) * | 2020-11-20 | 2023-12-07 | シンク・セラピューティクス・インコーポレイテッド | 最適化ペプチドワクチンの組成物および方法 |
| US12275766B2 (en) * | 2020-12-23 | 2025-04-15 | Janssen Biotech, Inc. | Neoantigen peptide mimics |
| CN112666358A (zh) * | 2021-01-14 | 2021-04-16 | 深圳裕康医学检验实验室 | 一种使用外周血检测抗原免疫原性的方法 |
| CN113150140B (zh) * | 2021-01-25 | 2022-11-04 | 山西农业大学 | 一种sox6二价纳米抗体及其应用 |
| WO2022179568A1 (en) * | 2021-02-25 | 2022-09-01 | Westlake Therapeutics (Hangzhou) Co., Limited | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
| US20250136711A1 (en) * | 2021-03-16 | 2025-05-01 | Shanghai Biotroy Biotechnique Co., Ltd | Semenogelin neutralizing antibody and epitope and application thereof |
| CN114163513B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
| CN113861283B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与肺癌驱动基因突变相关的抗原肽及其应用 |
| CN114230656B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
| JP2024516542A (ja) * | 2021-04-06 | 2024-04-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｍｈｃクラスｉペプチドを含む方法および組成物 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| IL282814A (en) * | 2021-04-29 | 2022-11-01 | Yeda Res & Dev | T cell receptors directed against ras-derived recurrent neoantigens |
| JP2024517793A (ja) | 2021-04-30 | 2024-04-23 | ティゲン・ファーマ・ソシエテ・アノニム | 単一容器リンパ球拡大 |
| CN113527464B (zh) * | 2021-07-19 | 2024-10-18 | 新景智源生物科技(苏州)有限公司 | 识别mboat2的tcr |
| CN119241504A (zh) | 2021-08-26 | 2025-01-03 | 沃拉斯查疗法公司 | Kif18a的螺吲哚啉抑制剂 |
| CN117805372A (zh) * | 2021-08-30 | 2024-04-02 | 河南中医药大学 | 一种生物标记物在制备检测桥本甲状腺炎脾肾阳虚证的试剂或试剂盒中的应用 |
| CN114085281A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤抗原表位肽及其多聚体和应用 |
| CN114085282A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤新生抗原表位肽Pep6及其多聚体和应用 |
| KR20240099338A (ko) * | 2021-10-28 | 2024-06-28 | 제넨테크, 인크. | 치료 개입을 위해 mhc 관련 항원을 식별하는 시스템 및 방법 |
| WO2023081655A1 (en) * | 2021-11-02 | 2023-05-11 | Fred Hutchinson Cancer Center | T cell immunotherapy for hematologic malignancies having an sf3b1 mutation |
| KR102818249B1 (ko) | 2021-11-11 | 2025-06-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
| KR102753583B1 (ko) | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| CN114177274A (zh) * | 2021-12-13 | 2022-03-15 | 中国医学科学院微循环研究所 | Tdrd10蛋白及其编码基因在制备肿瘤治疗药物中的应用、及肿瘤治疗药物 |
| JP2024546923A (ja) * | 2021-12-16 | 2024-12-26 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Ｐ５３腫瘍抗原を標的とするｍａｎａｂｏｄｙ及び使用方法 |
| KR102732909B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732910B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732912B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732913B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732911B1 (ko) | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| TW202340474A (zh) * | 2022-01-11 | 2023-10-16 | 大陸商深圳市珈鈺生物科技有限公司 | 樹突細胞腫瘤疫苗和其用途 |
| EP4476268A2 (en) * | 2022-02-07 | 2024-12-18 | Ubiquitx | Beta-catenin protein degradation |
| CN114524872A (zh) * | 2022-03-09 | 2022-05-24 | 广州诺诚生物技术研发有限公司 | 一种用于乳腺癌检测的单克隆抗体及其试剂盒 |
| KR102772405B1 (ko) * | 2022-06-10 | 2025-02-26 | (주)케어젠 | 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도 |
| CN115327125A (zh) * | 2022-07-14 | 2022-11-11 | 宁波大学 | 一种蛋白质inf2在制备肝癌诊断标志物中的应用 |
| CN117586344B (zh) * | 2022-08-12 | 2025-07-25 | 上海交通大学医学院附属瑞金医院 | 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用 |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| CN115651984B (zh) * | 2022-10-20 | 2023-04-14 | 山东大学 | 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用 |
| EP4612276A1 (en) | 2022-11-02 | 2025-09-10 | Tigen Pharma SA | Expansion of lymphocytes |
| EP4368189A1 (en) * | 2022-11-09 | 2024-05-15 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms |
| CN116024217A (zh) * | 2023-01-16 | 2023-04-28 | 陕西师范大学 | Mff作为靶点在制备治疗卵巢癌和/或评估患卵巢癌风险产品中的应用 |
| WO2024261339A1 (en) | 2023-06-23 | 2024-12-26 | Tigen Pharma Sa | Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations |
| CN116948004B (zh) * | 2023-09-13 | 2023-11-21 | 成都朗谷生物科技股份有限公司 | 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用 |
| WO2025064339A1 (en) * | 2023-09-18 | 2025-03-27 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| CN117567591B (zh) * | 2024-01-11 | 2024-04-26 | 中国人民解放军总医院 | 一种用于研究Tmem247蛋白的新型鼠源Tmem247抗体制备方法和应用 |
| TW202539700A (zh) * | 2024-01-16 | 2025-10-16 | 美商建南德克公司 | 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法 |
| LU103243B1 (en) | 2024-02-09 | 2025-08-11 | PMCR GmbH | Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same |
| WO2025168848A1 (en) | 2024-02-09 | 2025-08-14 | IMMUNEO Therapeutics GmbH | Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same |
| CN118745217B (zh) * | 2024-02-29 | 2025-03-04 | 漯河医学高等专科学校 | Obscn新抗原表位肽及其在制备防治肿瘤的药物中的应用 |
| CN118326008A (zh) * | 2024-04-18 | 2024-07-12 | 香港大学深圳医院 | 一种基于panel基因测序数据的肿瘤新抗原、筛选方法及应用 |
| CN118955677B (zh) * | 2024-05-29 | 2025-07-22 | 北京艺升控股有限公司 | 一种抗原肽及其应用 |
| CN119320833B (zh) * | 2024-12-18 | 2025-07-11 | 南京农业大学 | 一种与鸡双黄蛋性状相关的ston1基因分子标记引物及其应用 |
| CN121059808A (zh) * | 2025-11-05 | 2025-12-05 | 哈尔滨医科大学 | Pwwp2b作为靶点在制备白血病治疗药物中的应用 |
Family Cites Families (279)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
| US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
| US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
| US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US4816540A (en) | 1987-06-12 | 1989-03-28 | Yasuhiko Onishi | Cationic graft-copolymer |
| US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
| US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| CA2005291C (en) | 1988-12-30 | 1999-01-26 | Beverly Dale | Feline infectious peritonitis virus diagnostic tools |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| EP0800830A3 (en) | 1989-11-03 | 1999-03-17 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| US5198223A (en) | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
| WO1992014486A1 (en) | 1991-02-22 | 1992-09-03 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE | Transmission blocking vaccine against malaria |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| ATE247163T1 (de) | 1991-03-07 | 2003-08-15 | Virogenetics Corp | Gentechnologisch hergestellter stamm für impfstoffe |
| US5766597A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US5756101A (en) | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
| WO1995030018A2 (en) | 1994-04-29 | 1995-11-09 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
| US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
| US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
| HUP0000421A2 (hu) | 1996-10-17 | 2000-06-28 | Oxford Biomedica (Uk) Limited | Retrovirális vektorok |
| US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| ATE466948T1 (de) | 1997-03-11 | 2010-05-15 | Univ Minnesota | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle |
| US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| CA2304168A1 (en) | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| CA2338780C (en) | 1998-07-28 | 2007-01-02 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing medicinal substance at targeted site in intestine |
| CN1367830A (zh) | 1998-10-05 | 2002-09-04 | 路德维哥癌症研究院 | 癌症相关抗原及其应用 |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| JP2003501043A (ja) | 1999-05-28 | 2003-01-14 | ターゲティッド ジェネティクス コーポレイション | 腫瘍壊死因子（ｔｎｆ）関連障害において、ｔｎｆのレベルを低下させるための方法および組成物 |
| ATE512666T1 (de) | 1999-06-29 | 2011-07-15 | Epimmune Inc | Hla-bindende peptide und ihre verwendungen |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| WO2001055177A2 (en) | 2000-01-28 | 2001-08-02 | Statens Serum Institut | Methods to identify ctl epitopes of hiv |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU780696B2 (en) | 2000-03-14 | 2005-04-14 | Bavarian Nordic A/S | Altered strain of the modified vaccinia virus ankara (MVA) |
| US6686184B1 (en) | 2000-05-25 | 2004-02-03 | President And Fellows Of Harvard College | Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks |
| GB0024550D0 (enExample) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| KR100910297B1 (ko) | 2000-11-23 | 2009-08-03 | 버베리안 노딕 에이/에스 | 변형된 백시니아 앙카라 바이러스 변형체 |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US6923973B1 (en) | 2001-02-22 | 2005-08-02 | Board Of Regents, The University Of Texas System | Peptide and DNA immunization against Coccidioides immitis infections |
| US20030104008A1 (en) | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
| AU2002322280A1 (en) * | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| CA2457652C (en) | 2001-08-31 | 2012-08-07 | Avidex Limited | Soluble t cell receptor |
| AU2002336446B2 (en) | 2001-09-06 | 2008-03-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US7670781B2 (en) | 2002-01-03 | 2010-03-02 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal |
| AU2003234736B2 (en) | 2002-04-12 | 2008-09-25 | E. R. Squibb & Sons, L.L.C. | Methods of treatment using CTLA-4 antibodies |
| EP1839672A3 (en) | 2002-04-19 | 2007-11-21 | Bavarian Nordic A/S | Modified vaccinia virus Ankara for the vaccination of neonates |
| US8227432B2 (en) | 2002-04-22 | 2012-07-24 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| AU2003251483A1 (en) | 2002-06-05 | 2003-12-22 | Case Western Reserve University | Methods and compositions for detecting cancers |
| PT1512014E (pt) | 2002-06-13 | 2009-11-10 | Merck Patent Gmbh | Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante |
| JP2006507921A (ja) | 2002-06-28 | 2006-03-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 流体分散のための方法および装置 |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| AU2003264514A1 (en) | 2002-09-20 | 2004-04-08 | Chugai Seiyaku Kabushiki Kaisha | Wt1 substitution peptides |
| CA2500687A1 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
| WO2004044004A2 (en) | 2002-11-09 | 2004-05-27 | Avidex Limited | T cell receptor display |
| CA2511625A1 (en) | 2002-12-23 | 2004-07-15 | City Of Hope | Modified vaccinia ankara expressing p53 in cancer immunotherapy |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| EP2266687A3 (en) | 2003-04-10 | 2011-06-29 | The President and Fellows of Harvard College | Formation and control of fluidic species |
| PL1620456T3 (pl) | 2003-04-18 | 2014-06-30 | Ose Pharma Int Sa | Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje |
| US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
| ES2307053T3 (es) | 2003-07-24 | 2008-11-16 | Merial Limited | Formulaciones de vacuna que comprenden una emulsion de aceite en agua. |
| WO2005021151A1 (en) | 2003-08-27 | 2005-03-10 | President And Fellows Of Harvard College | Electronic control of fluidic species |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US7084247B2 (en) | 2004-03-11 | 2006-08-01 | Peptimmune, Inc. | Identification of self and non-self antigens implicated in autoimmune diseases |
| WO2005092928A1 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| AU2005245664B2 (en) | 2004-05-19 | 2012-02-02 | Adaptimmune Limited | High affinity NY-ESO T cell receptor |
| JP4972549B2 (ja) | 2004-05-19 | 2012-07-11 | イムノコア リミテッド | Ｔ細胞レセプターを改善する方法 |
| US20060008468A1 (en) | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| WO2006020071A2 (en) | 2004-07-16 | 2006-02-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines against aids comprising cmv/r-nucleic acid constructs |
| US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
| EP2573185A3 (en) | 2005-02-16 | 2013-06-05 | Lentigen Corporation | Lentiviral vectors and their use |
| US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
| EP2248578B1 (en) | 2005-03-04 | 2012-06-06 | President and Fellows of Harvard College | Method for forming multiple emulsions |
| AR052741A1 (es) | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
| US20090142363A1 (en) | 2005-08-03 | 2009-06-04 | Medical And Biological Laboratories, Co., Ltd. | Cytotoxic t-cell epitope peptide and use thereof |
| EP4174179B1 (en) | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| US20070112754A1 (en) | 2005-11-15 | 2007-05-17 | Honeywell International Inc. | Method and apparatus for identifying data of interest in a database |
| US20100137163A1 (en) | 2006-01-11 | 2010-06-03 | Link Darren R | Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors |
| EP2004316B8 (en) | 2006-01-27 | 2011-04-13 | President and Fellows of Harvard College | Fluidic droplet coalescence |
| US8793895B2 (en) | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Lyophilization system and method |
| WO2007101227A2 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| US20080014589A1 (en) | 2006-05-11 | 2008-01-17 | Link Darren R | Microfluidic devices and methods of use thereof |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| JP2009538607A (ja) | 2006-06-02 | 2009-11-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 患者が免疫療法に対する応答者であるかどうかを同定する方法 |
| US20100035973A1 (en) | 2006-07-17 | 2010-02-11 | Nationwide Children's Hospital, Inc. | Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| WO2008038002A2 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | T cell therapies |
| US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
| US8349167B2 (en) | 2006-12-14 | 2013-01-08 | Life Technologies Corporation | Methods and apparatus for detecting molecular interactions using FET arrays |
| US9045556B2 (en) | 2007-02-07 | 2015-06-02 | Nec Corporation | Therapeutic agent for cancer |
| WO2008109075A2 (en) | 2007-03-05 | 2008-09-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| WO2008118691A2 (en) | 2007-03-22 | 2008-10-02 | The Regents Of The University Of Colorado | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| CN101796070A (zh) | 2007-05-31 | 2010-08-04 | 莱顿教学医院 | p53肽疫苗 |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| AU2008296733B2 (en) | 2007-08-08 | 2013-07-11 | The Board Of Regents Of The University Of Texas System | VEGFR-1/NRP-1 targeting peptides |
| US20100204118A1 (en) | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| CN104873962B (zh) | 2007-10-25 | 2019-04-26 | 东丽株式会社 | 免疫诱导剂 |
| WO2009086472A2 (en) | 2007-12-28 | 2009-07-09 | John Wayne Cancer Institute | Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer |
| JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス，インコーポレイテッド | 心不全の治療用のｒｎａ干渉 |
| WO2009102909A2 (en) | 2008-02-15 | 2009-08-20 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| CA2718975A1 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
| ES2840750T3 (es) | 2008-09-22 | 2021-07-07 | Baylor College Medicine | Métodos y composiciones para generar una respuesta inmune induciendo CD40 y adaptadores del receptor de reconocimiento de patrones |
| KR20110069092A (ko) | 2008-10-17 | 2011-06-22 | 제넨테크, 인크. | 치료 방법 |
| US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
| AU2009317161B2 (en) | 2008-11-24 | 2014-09-11 | Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
| PT2413956T (pt) | 2009-04-02 | 2016-12-30 | Vaxon Biotech | Identificação, optimização e utilização de epitopos crípticos hla-a24 para imunoterapia |
| RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| CN102652015B (zh) | 2009-12-10 | 2016-08-03 | 默克专利有限公司 | 包含寡肽、优选西仑吉肽的药物组合物 |
| US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| EP2517025B1 (en) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Methods for reducing the exchange of molecules between droplets |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| TW201138782A (en) | 2010-04-26 | 2011-11-16 | Besins Healthcare Lu Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
| DK3023788T3 (da) * | 2010-05-14 | 2020-04-27 | Massachusetts Gen Hospital | Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| ES2536791T3 (es) | 2010-05-28 | 2015-05-28 | Oxford Biomedica (Uk) Ltd | Administración de vectores lentivirales al cerebro |
| MX343671B (es) | 2010-06-02 | 2016-11-16 | Abraxis Bioscience Llc * | Metodos de tratamiento de cancer de vejiga. |
| DK2608799T3 (en) | 2010-08-24 | 2019-03-18 | Univ Pittsburgh Commonwealth Sys Higher Education | INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB2506760B (en) | 2011-01-14 | 2015-07-22 | Genefirst Ltd | Allele specific primers for EGFR exon 21 specific mutations |
| EP2478915A1 (en) | 2011-01-24 | 2012-07-25 | Genticel | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
| US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
| HRP20230443T1 (hr) | 2011-05-24 | 2023-09-15 | BioNTech SE | Individualizirana cjepiva protiv raka |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| JP2014526892A (ja) | 2011-08-18 | 2014-10-09 | ネステク ソシエテ アノニム | 対立遺伝子多型を検出するための組成物及び方法 |
| SG11201400432VA (en) * | 2011-09-06 | 2014-08-28 | Agency Science Tech & Res | Polypeptide vaccine |
| AU2012309830B2 (en) | 2011-09-15 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage |
| WO2013040371A2 (en) | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013086464A1 (en) | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
| US20130210014A1 (en) | 2012-02-10 | 2013-08-15 | Jeff Sharman | Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients |
| AU2013221642A1 (en) | 2012-02-15 | 2014-09-25 | Janssen Diagnostics, Llc | Highly sensitive method for detecting low frequency mutations |
| CN104168917A (zh) | 2012-03-09 | 2014-11-26 | 肿瘤疗法科学股份有限公司 | 含有肽的医药组合物 |
| RU2018130123A (ru) | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
| KR20200075023A (ko) | 2012-05-04 | 2020-06-25 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| EP2861761A1 (en) | 2012-06-15 | 2015-04-22 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
| AU2013289939B2 (en) | 2012-07-12 | 2018-08-09 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| WO2014009535A2 (en) | 2012-07-12 | 2014-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| WO2014011987A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating car t cells |
| MX2015000979A (es) | 2012-07-27 | 2015-11-23 | Univ Illinois | Ingenieria de receptores de celulas t. |
| EP2897631A4 (en) | 2012-08-31 | 2016-10-05 | Univ Virginia Patent Found | TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS |
| WO2014047561A1 (en) | 2012-09-21 | 2014-03-27 | The Broad Institute Inc. | Compositions and methods for labeling of agents |
| JP6401704B2 (ja) | 2012-10-10 | 2018-10-10 | サンガモ セラピューティクス， インコーポレイテッド | Ｔ細胞を修飾する化合物およびその使用 |
| WO2014056986A1 (en) | 2012-10-11 | 2014-04-17 | Universitat De Barcelona | Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll) |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| EP2925447B1 (en) | 2012-11-30 | 2020-04-08 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
| CN105102467B (zh) | 2013-02-07 | 2019-01-22 | 新泽西鲁特格斯州立大学 | 高度选择性核酸扩增引物 |
| KR102363191B1 (ko) | 2013-02-26 | 2022-02-17 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| US9844569B2 (en) | 2013-03-01 | 2017-12-19 | The United State Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive T cells from peripheral blood |
| EP2961415B1 (en) | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| WO2014150924A2 (en) | 2013-03-15 | 2014-09-25 | The Broad Institute, Inc. | Accurate typing of hla through exome sequencing |
| KR102858313B1 (ko) * | 2013-04-07 | 2025-09-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 개인맞춤화 신생물 백신을 위한 조성물 및 방법 |
| WO2014172606A1 (en) | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| WO2014184744A1 (en) | 2013-05-13 | 2014-11-20 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| EP3004877A4 (en) | 2013-06-06 | 2017-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| KR102429859B1 (ko) | 2013-12-06 | 2022-08-04 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생물 백신을 위한 제형 |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| CA2953277A1 (en) | 2014-06-05 | 2015-12-10 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Means and methods for determining t cell recognition |
| CN106715723B (zh) | 2014-08-07 | 2021-03-30 | 法马西斯特有限责任公司 | 测定样品中pik3ca突变状态的方法 |
| EP3198031A1 (en) | 2014-09-22 | 2017-08-02 | Dana Farber Cancer Institute, Inc. | Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US20190099475A1 (en) * | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| BR112017022845A2 (pt) * | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| CN108138221B (zh) | 2015-05-10 | 2021-11-05 | 康代思锐公司 | 用于检测核酸的超高灵敏度探针 |
| WO2016187508A2 (en) * | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
| TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| PT3436048T (pt) | 2016-03-31 | 2025-08-06 | Biontech Us Inc | Neoantigénios e métodos da sua utilização |
| WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
-
2016
- 2016-05-20 WO PCT/US2016/033452 patent/WO2016187508A2/en not_active Ceased
- 2016-05-20 CR CR20170584A patent/CR20170584A/es unknown
- 2016-05-20 CA CA2986235A patent/CA2986235A1/en active Pending
- 2016-05-20 CN CN202211239802.9A patent/CN116196401A/zh active Pending
- 2016-05-20 KR KR1020177036611A patent/KR20180010229A/ko not_active Ceased
- 2016-05-20 KR KR1020247038026A patent/KR20240166604A/ko active Pending
- 2016-05-20 IL IL302102A patent/IL302102A/en unknown
- 2016-05-20 MY MYPI2017001689A patent/MY190974A/en unknown
- 2016-05-20 TW TW114108178A patent/TW202523682A/zh unknown
- 2016-05-20 JP JP2017560196A patent/JP6913032B2/ja active Active
- 2016-05-20 EP EP16732018.3A patent/EP3297660A2/en active Pending
- 2016-05-20 TW TW105115840A patent/TWI806815B/zh active
- 2016-05-20 CR CR20230191A patent/CR20230191A/es unknown
- 2016-05-20 PE PE2017002446A patent/PE20180670A1/es unknown
- 2016-05-20 CN CN201680042436.4A patent/CN108025048B/zh active Active
- 2016-05-20 IL IL255769A patent/IL255769B2/en unknown
- 2016-05-20 IL IL294183A patent/IL294183B2/en unknown
- 2016-05-20 CR CR20200476A patent/CR20200476A/es unknown
- 2016-05-20 TW TW112105056A patent/TWI878795B/zh active
- 2016-05-20 AU AU2016264623A patent/AU2016264623B2/en active Active
- 2016-05-20 BR BR112017024797-6A patent/BR112017024797A2/pt active Search and Examination
- 2016-05-20 HK HK18111576.9A patent/HK1252267A1/zh unknown
- 2016-05-20 US US15/575,328 patent/US10835585B2/en active Active
- 2016-05-20 RU RU2017144467A patent/RU2733754C2/ru active
- 2016-05-20 MX MX2017014700A patent/MX2017014700A/es unknown
-
2017
- 2017-11-16 MX MX2024006806A patent/MX2024006806A/es unknown
- 2017-11-16 MX MX2023005122A patent/MX2023005122A/es unknown
- 2017-11-20 CL CL2017002945A patent/CL2017002945A1/es unknown
- 2017-12-13 CO CONC2017/0012835A patent/CO2017012835A2/es unknown
- 2017-12-15 PH PH12017502321A patent/PH12017502321A1/en unknown
- 2017-12-20 EC ECIEPI201784137A patent/ECSP17084137A/es unknown
-
2020
- 2020-04-27 US US16/859,252 patent/US20200368337A1/en active Pending
-
2021
- 2021-07-09 JP JP2021114423A patent/JP7282834B2/ja active Active
-
2022
- 2022-09-28 AU AU2022241521A patent/AU2022241521B2/en active Active
-
2023
- 2023-05-17 JP JP2023081513A patent/JP2023103405A/ja active Pending
- 2023-08-16 CL CL2023002421A patent/CL2023002421A1/es unknown
-
2025
- 2025-06-23 AU AU2025204711A patent/AU2025204711A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522822A5 (enExample) | ||
| Morris et al. | Interaction of radiation therapy with molecular targeted agents | |
| Glynne-Jones et al. | Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control | |
| ES2617983T3 (es) | Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores | |
| Tucci et al. | Does cilengitide deserve another chance? | |
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| BR122023025321A2 (pt) | Uso de anticorpos anti-b7-h1 e anti-ctla-4 | |
| JP2017515841A5 (enExample) | ||
| Kang et al. | Novel chemotherapeutics and other therapies for treating high-grade glioma | |
| Roman Souza et al. | Clinical trials targeting neurofibromatoses-associated tumors: a systematic review | |
| Holubec et al. | The role of cetuximab in the treatment of metastatic colorectal cancer | |
| Mellinghoff et al. | Signal transduction inhibitors and antiangiogenic therapies for malignant glioma | |
| CN115803629A (zh) | 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 | |
| JP2014510047A5 (enExample) | ||
| JP2018530568A5 (enExample) | ||
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| Chamberlain | Evolving strategies: future treatment of glioblastoma | |
| JP2021504378A (ja) | 改良されたがんの処置 | |
| Kaliks | An update on clinical oncology for the non-oncologist | |
| Landi et al. | Epct-13. Cmv pp65 RNA-pulsed dendritic cell vaccines for pediatric glioblastoma and medulloblastoma: Phase i trial results | |
| Alexander et al. | Current and future directions for Phase II trials in high-grade glioma | |
| Trédaniel et al. | Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer | |
| Horn et al. | P1. 13-02 eXalt3: phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients | |
| Ferguson et al. | Vaccination against tumour blood vessels in colorectal cancer | |
| Brose et al. | 51LBA Completion of a Phase II study of sorafenib for advanced thyroid cancer |